Entries |
Document | Title | Date |
20080200398 | Compounds For Enzyme Inhibition - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. | 08-21-2008 |
20080200399 | Compounds for Treating Neurologic Diseases, Otologic Diseases, or Ophthalmologic Diseases and Methods of Use Thereof - Described herein are compounds and methods for treating or preventing a neurologie, otologic, or ophthalmologic disease in a subject. Also described herein are compounds that can be used as therapeutics. | 08-21-2008 |
20080200400 | DERMATOLOGICAL COMPOSITIONS INCLUDING OLIGOPEPTIDES FOR INCREASING SKIN SENSITIVITY AND NEURONAL PERCEPTION - The invention relates to dermatological compositions including at least one oligopeptide with a sequence of 4, 5 or 6 amino acids and/or a derivative thereof as means for increasing the sensitivity of skin, wherein the amino acid sequence comprises the dipeptide sequence Ile-Pro and/or Pro-Ile. | 08-21-2008 |
20080207527 | Bicyclic Compounds Which Inhibit Beta-Secretase Activity and Methods of Use Thereof - The present invention provides bicyclic beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease. | 08-28-2008 |
20080207528 | HCV PROTEASE INHIBITORS - This invention relates to the compounds of formula (I) shown below. Each variable in formula (I) is defined in the specification. These compounds can be used to treat hepatitis C virus infection. | 08-28-2008 |
20080214471 | Method for inhibition of viral infection - The invention is directed to inhibiting viral morphogenesis and viral infection. In particular, it concerns effecting such inhibition by inhibiting the prenylation or post prenylation reactions of a viral or host protein. | 09-04-2008 |
20080214472 | Small Peptides And Methods For Treatment Of Arthritis - Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucous release into airways of a patient, a method for blocking IgE activation of a lymphocyte, a method for stabilizing the cell membrane of a lymphocyte, thereby preventing their further involvement in the increased inflammatory response to an IgE antigen challenge, and a method for inhibiting the migration of T-cells. Such methods involve administering to said patient a therapeutically effective amount of a peptide having the formula f-Met-Leu-X, wherein X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr. | 09-04-2008 |
20080214473 | Small Peptides And Methods For Treatment Of Chronic Obstruction Pulmonary Disease - Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucous release into airways of a patient, a method for blocking IgE activation of a lymphocyte, a method for stabilizing the cell membrane of a lymphocyte, thereby preventing their further involvement in the increased inflammatory response to an IgE antigen challenge, and a method for inhibiting the migration of T-cells. Such methods involve administering to said patient a therapeutically effective amount of a peptide having the formula f-Met-Leu-X, wherein X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr. | 09-04-2008 |
20080214474 | Small Peptides And Methods For Treatment Of Chronic Inflammatory Bowel Disease - Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucous release into airways of a patient, a method for blocking IgE activation of a lymphocyte, a method for stabilizing the cell membrane of a lymphocyte, thereby preventing their further involvement in the increased inflammatory response to an IgE antigen challenge, and a method for inhibiting the migration of T-cells. Such methods involve administering to said patient a therapeutically effective amount of a peptide having the formula f-Met-Leu-X, wherein X is selected from the group consisting of Tyr, Try-Phe, Phe-Phe and Phe-Tyr. | 09-04-2008 |
20080214475 | Small Peptides And Methods For Inhibiting The Mucous Release Into Airways - Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucous release into airways of a patient, a method for blocking IgE activation of a lymphocyte, a method for stabilizing the cell membrane of a lymphocyte, thereby preventing their further involvement in the increased inflammatory response to an IgE antigen challenge, and a method for inhibiting the migration of T-cells. Such methods involve administering to said patient a therapeutically effective amount of a peptide having the formula f-Met-Leu-X, wherein X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr. | 09-04-2008 |
20080214476 | Small Peptides And Methods For Blocking IgE Mediated Activation Of An Immune Cell - Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucous release into airways of a patient, a method for blocking IgE activation of a lymphocyte, a method for stabilizing the cell membrane of a lymphocyte, thereby preventing their further involvement in the increased inflammatory response to an IgE antigen challenge, and a method for inhibiting the migration of T-cells. Such methods involve administering to said patient a therapeutically effective amount of a peptide having the formula f-Met-Leu-X, wherein X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr. | 09-04-2008 |
20080214477 | Small Peptides And Methods For Inhibiting The Migration Of T-Cells - Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucous release into airways of a patient, a method for blocking IgE activation of a lymphocyte, a method for stabilizing the cell membrane of a lymphocyte, thereby preventing their further involvement in the increased inflammatory response to an IgE antigen challenge, and a method for inhibiting the migration of T-cells. Such methods involve administering to said patient a therapeutically effective amount of a peptide having the formula f-Met-Leu-X, wherein X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr. | 09-04-2008 |
20080214478 | Small Peptides And Methods For Inhibiting The Infiltration Of Eosinophils Into Airways - Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucous release into airways of a patient, a method for blocking IgE activation of a lymphocyte, a method for stabilizing the cell membrane of a lymphocyte, thereby preventing their further involvement in the increased inflammatory response to an IgE antigen challenge, and a method for inhibiting the migration of T-cells. Such methods involve administering to said patient a therapeutically effective amount of a peptide having the formula f-Met-Leu-X, wherein X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr. | 09-04-2008 |
20080227724 | Anti-Inflammatory Agents - The invention relates to the use of 3-aminocaprolactam derivatives for preparing a medicament intended to prevent or treat inflammatory disorders, and uses compounds of general formula (I) or a pharmaceutically acceptable salts thereof; | 09-18-2008 |
20080227725 | Cosmetic or pharmaceutical composition comprising peptides, uses and treatment processes - The present invention relates to the use of at least one peptide, with the sequence (AA)n-Arg-Gly-Ser-(AA)n, where (AA) is any amino acid or one of its derivatives, and N is an integer between 0 and 3, as an active ingredient, in or for the preparation of a cosmetic and/or dermatological and/or pharmaceutical composition. The invention also relates to its use in order to treat, inter alia, the cutaneous manifestations of aging and/or its use in order to act against cellulite. The invention is, in the same way, related to a composition containing it as well as a process of cosmetic treatment of the skin using the said peptide or the said composition. | 09-18-2008 |
20080242620 | Biologically active peptide comprising tyrosyl-seryl-valine (YSV) - The tripeptide Tyrosyl-seryl-valine is disclosed with its use as a pharmaceutical composition. A method is also disclosed making a pharmaceutical composition comprising providing the tripeptide Tyrosyl-seryl-valine and mixing said tripeptide with a pharmaceutical acceptable carrier. | 10-02-2008 |
20080242621 | YEAST HYDROLYSATE CONTAINING CYCLO-HIS-PRO AND METHOD OF MAKING AND USING THE SAME - Provided is a method for producing a yeast hydrolysate containing Cyclo-His-Pro (CHP), via an enzyme-substrate reaction by addition of a flavourzyme to a yeast suspension. Herein, the yeast hydrolysate obtained after the enzyme-substrate reaction is filtered or centrifuged to recover a supernatant, and the supernatant may be subjected to (1) drying after ultrafiltration, or (2) drying after activated carbon treatment, or (3) combined treatment of (1) and (2). The method of the present invention enables production of the yeast hydrolysate having a remarkably high content of Cyclo-His-Pro (CHP), as compared to conventional foods. In particular, purification of the thus-resulting yeast hydrolysate can enhance the content of Cyclo-His-Pro (CHP) 10-fold to 85-fold higher than prior to the purification thereof. The yeast hydrolysate containing Cyclo-His-Pro (CHP) of the present invention exerts blood glucose-lowering effects and glucose tolerance-improving effects, simultaneously with an enhancement of insulin sensitivity. | 10-02-2008 |
20080249028 | Thyrotropin-Releasing Hormone Analogs and Method of Use - The invention provides a method of modulating blood glucose levels by treating or preventing pancreas-related disorders with thyrotropin-releasing hormone (TRH) or a TRH derivative. Diabetes mellitus, pancreatic islet destruction, pancreatic beta cell malfunction, and hyperglycemia-related malfunction are preferably treated or prevented. | 10-09-2008 |
20080249029 | Methods for Treating Skin Pigmentation - This invention relates to methods and compositions for bringing about changes in skin pigmentation. More particularly, this invention relates to compounds which affect melanogenesis and can be used as depigmenting agents or as agents for darkening skin utilizing the PAR-2 pathway. | 10-09-2008 |
20080255055 | Use of Derivatives of Dipeptides for the Manufacture of of a Medicament for the Treamtent of Microbial Infections - The invention relates to compositions comprising a compound based on the general formula (I) R | 10-16-2008 |
20080261894 | Combination Therapy with Glatiramer Acetate and Rasagiline for the Treatment of Multiple Sclerosis - The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, wherein the amounts when taken together are effective to alleviate a symptom of the form of multiple sclerosis in the subject so as to thereby treat the subject. The subject invention also provides a package comprising glatiramer acetate, rasagiline or the pharmaceutically acceptable salt thereof and instructions for use of the together to alleviate a symptom of a form of multiple sclerosis in a subject. The subject invention further provides a pharmaceutical combination comprising separate dosage forms of an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, which combination is useful to alleviate a symptom of a form of multiple sclerosis in a subject. | 10-23-2008 |
20080269140 | Conformationally Constrained Smac Mimetics and the Uses Thereof - The invention relates to conformationally constrained mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis. | 10-30-2008 |
20080269141 | Peptide Substance Restoring Myocardium Function - The invention refers to the pharmaceutical means for the treatment of cardiovascular diseases and can be used as a substance restoring myocardium function in the course of treatment for different forms of this pathology. | 10-30-2008 |
20080269142 | ENDOGENOUS THIADIAZABICYCLO GLUTATHIONE-ADDUCT - This invention relates to mediators of apoptosis. Specifically, the invention relates to thiadiazabicyclo-4-oxo-2(E)-nonenal-Glutathione adduct as a novel agent for inducing apoptosis in cells depleted of GSH. | 10-30-2008 |
20080269143 | Dmt-Derivative Compounds and Related Compositions and Methods of Use - The present invention relates to symmetric and asymmetric dimeric Dmt (2′,6′-ditnethyl) compounds and Dmt derivative compounds with dual δ and μ opioid receptor antagonist activity. Also, the present invention provides compositions comprising these compounds and it provides methods of using these compounds. | 10-30-2008 |
20080274982 | Peptide Substance Restoring Respiratory Organs Function - The invention refers to the medicinal remedies for respiratory system diseases treatment and may be applied as a substance, capable of restoring respiratory organs functions and used for treatment of different forms of lung pathology. There is proposed a biologically active new tetrapeptide alanyl-glutamyl-aspartyl-leucine of the general formula Ala-Glu-Asp-Leu, capable of restoring respiratory organs function. There is proposed a pharmaceutical substance, containing as an active peptide agent an effective amount of tetrapeptide alanyl-glutamyl-aspartyl-leucine of the general formula Ala-Glu-Asp-Leu, which if used in the medical preparation contributes to the restoration of the respiratory organs function. | 11-06-2008 |
20080274983 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases - Ophthalmically acceptable compositions used in arresting the development of cataracts or macular degeneration comprising a pharmaceutically acceptable carrier or diluent and a compound having the formula: | 11-06-2008 |
20080287370 | Boronic Acid Salts Useful in Parenteral Formulations - Salts of a peptide boronic acid drug, for example of Cbz-(R)-Phe-(S)—Pro-(R)-Mpg-B(OH) | 11-20-2008 |
20080287371 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR MODULATION OF THE MIGRATING MOTOR COMPLEX - The present invention relates to novel conformationally-defined macrocyclic compounds that bind to and/or are functional modulators of the motilin receptor including subtypes, isoforms and/or variants thereof. These macrocyclic compounds are useful as therapeutics for a range of gastrointestinal disorders, in particular those in which suppression or inhibition of the migrating motor complex (MMC) is effective or malfunction of gastric motility or increased motilin secretion is observed, such as hypermotilinemia, imitable bowel syndrome, dyspepsia, including gallbladder dyspepsia, diarrhea, cancer treatment-related diarrhea, cancer-induced diarrhea, chemotherapy-induced diarrhea, radiation enteritis, radiation-induced diarrhea, stress-induced diarrhea, chronic diarrhea, AIDS-related diarrhea, | 11-20-2008 |
20080300191 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF - Disclosed are protease inhibitors for coronaviruses and SARS-CoV, or picornaviruses, and the use of these protease inhibitors for preventing, reducing, ameliorating and treating a disease or condition caused by coronaviruses and SARS-CoV, or picornaviruses. Also disclosed are methods of reducing or preventing the spread of coronavirus, or picornaviruses, and preventing or reducing the replication of coronavirus, or picornaviruses, with the compounds of the present invention | 12-04-2008 |
20080300192 | Auristatins Having an Aminobenzoic Acid Unit at the N Terminus - Auristatin-type peptides are disclosed which are highly cytotoxic, synthetically accessible, and can be conjugated to antibodies and other ligands. | 12-04-2008 |
20080306009 | Immunoregulatory compositions - The invention relates to compounds exhibiting immunoregulatory activity as determined by measuring the compound's ability to modulate production of NO by a cell. Preferred compounds include or consist of a sequence | 12-11-2008 |
20080312159 | Dendrimeric peptides, pharmaceutical compositions and methods of using the same - Novel dendrimeric peptide compounds are disclosed that have a formula represented by the following formula I: | 12-18-2008 |
20090005320 | COMPOSITIONS COMPRISING AMINO ACID BICARBONATE AND METHODS OF USE THEREOF - The invention relates to compositions comprising one or more ionic salts, each of said ionic salts consisting of a bicarbonate anion and a cation selected from the group consisting of an amino acid, an amino acid derivative, a di-peptide and a tri-peptide, and to methods of making and using said compositions. | 01-01-2009 |
20090012006 | Par-2 Antagonists - Compounds represented by the general formula (1) or salts thereof or solvates of both; PAR-2 antagonists containing the compounds; and preventive or therapeutic agents for PAR-2 related diseases containing the antagonists as the active ingredient: (1) wherein R | 01-08-2009 |
20090029925 | INTERACTION OF BIM WITH TRIM2, AN E3 UBIQUITIN LIGASE - Methods, compositions, and cells for drug screening based on interaction between (1) a Bim polypeptide and/or an E2 polypeptide and (2) a TRIM2 polypeptide, which is identical to or corresponds to a Bim-selective E3 ubiquitin ligase. Methods and compositions for treating cancer based on levels of Bim protein, TRIM2 protein, and active MAPK protein are also provided. | 01-29-2009 |
20090042809 | Blood Pressure Lowering Protein Hydrolysates - The present invention describes the tripeptide MAP and/or the tripeptide ITP and/or a salt thereof. | 02-12-2009 |
20090048181 | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis - The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of N-acetylcysteine or a pharmaceutically acceptable salt thereof, wherein the amounts when taken together are effective to alleviate a symptom of the form of multiple sclerosis in the subject so as to thereby treat the subject. Additionally, the subject invention provides a pharmaceutical composition comprising an amount of glatiramer acetate and an amount of N-acetylcysteine or a pharmaceutically acceptable salt thereof, wherein the amounts when taken together are effective to alleviate a symptom of a form of multiple sclerosis in a subject. The subject invention also provides a package comprising glatiramer acetate, N-acetylcysteine or a pharmaceutically acceptable salt thereof and instructions for use of the together to alleviate a symptom of a form of multiple sclerosis in a subject. The subject invention further provides a pharmaceutical combination comprising separate dosage forms of an amount of glatiramer acetate and an amount of N-acetylcysteine or a pharmaceutically acceptable salt thereof, which combination is useful to alleviate a symptom of a form of multiple sclerosis in a subject. | 02-19-2009 |
20090048182 | Cosmetic Use of at Least One Natural Ac-N-Ser-Asp-Lys-Pro-Tetrapeptide or One of Its Analogues as Agent for Slowing Down Loss of Hair and/or Stimulating Hair Growth - The invention concerns the cosmetic use of at least one compound of formula (I) wherein: A | 02-19-2009 |
20090062213 | Small Molecule Inhibitors of PDZ Interactions - The present invention relates to compositions for use in the modulation of PDZ domain interactions with cognate ligands. Methods of assessing and characterizing PDZ domain interactions from various polypeptides also are provided. | 03-05-2009 |
20090069249 | METHODS FOR REDUCING OXIDATIVE STRESS IN A CELL WITH A SULFHYDRYL PROTECTED CLUTATHIONE PRODRUG - The present invention relates to compositions and methods for reducing oxidative stress in a cell, increasing glutathione levels in a cell, increasing L-cysteine levels in a cell and reducing hepatocytotoxicity by contacting a cell with a sulfhydryl protected glutathione prodrug or a sulfhydryl protected cysteine prodrug. | 03-12-2009 |
20090075906 | OLIGOPEPTIDES AND COMPOSITIONS CONTAINING THE OLIGOPEPTIDES - Oligopeptides according to formula (I) and/or (II), R | 03-19-2009 |
20090082281 | Compositions and methods for counteracting effects of reactive oxygen species and free radicals - Peptide compounds and methods for upregulating expression of a gene encoding an antioxidative enzyme, such as superoxide dismutase or catalase, to counteract harmful oxidative effects of reactive oxygen species and other free radicals are described. The peptide compounds may be used to treat or prevent diseases and conditions characterized by undesirable elevation of reactive oxygen species and other free radicals, to upregulate AP-1 gene expression, and to treat pain. The peptide compounds may be used as components of pharmaceuticals and dietary supplements. | 03-26-2009 |
20090088391 | Strains of Lactobacillus Helveticus which do not Ferment Lactose - The invention relates to novel strains of | 04-02-2009 |
20090093416 | CASPASE INHIBITORS AND USES THEREOF - The present invention provides a compound of formula I: | 04-09-2009 |
20090099096 | AZA-peptide protease inhibitors - The invention is related to compounds of Formula I: | 04-16-2009 |
20090099097 | Enzyme inhibition - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like and PGPH activities of the 20S proteasome can be selectively inhibited with the inventive compounds. The peptide-based compounds include an electron withdrawing group adjacent to the ring functionality, and the peptide include at least three peptide units. Among other therapeutic utilities, the peptide-based compounds exhibit anti-inflammatory and inhibition of cell proliferation, involving therapeutic applications for these compounds. | 04-16-2009 |
20090099098 | PEPTIDE SUBSTANCE ENHANCING CAPILLARIES RESISTANCE, PHARMACEUTICAL COMPOSITION ON ITS BASE AND METHOD OF ITS APPLICATION - The invention is related to the medicinal means of correction of metabolic vascular syndrome and diseases, associated with disordered vascular wall permeability and capillaries fragility, and can be used as a means of enhancing capillaries resistance. There is proposed a peptide lysyl-glutamyl-asparagine acid of the general formula H-Lys-Glu-Asp-OH sequence 1 [SEQ ID NO:1], revealing biological activity and capable of enhancing capillaries resistance. There is also proposed a pharmaceutical composition enhancing capillaries resistance, containing effective amount of peptide lysyl-glutamyl-asparagine acid of the general formula H-Lys-Glu-Asp-OH sequence 1 [SEQ ID NO: 1] as its active base and pharmaceutically acceptable carrier. This pharmaceutical composition is in form for parenteral administration. There is proposed a method for prevention and/or treatment of disorders of microcirculation in organs and tissues, consisting in the administration to a patient of the pharmaceutical composition, containing peptide lysyl-glutamyl-asparagine acid of the general formula H-Lys-Glu-Asp-OH sequence 1 [SEQ ID NO: 1] in the dose of 0.01-100 μg/kg of body weight at least once a day during a period necessary for attaining the therapeutic effect, such administration being performed parenterally. | 04-16-2009 |
20090105156 | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides - The invention relates to crystalline peptide keto epoxide compounds, methods of their preparation, and related pharmaceutical compositions. This invention also relates to methods for the preparation of amino acid keto-epoxides. Specifically, allylic ketones are stereoselectively converted to the desired keto epoxides. | 04-23-2009 |
20090105157 | PEPTIDE SUBSTANCE STIMULATING REGENERATION OF CENTRAL NERVOUS SYSTEM NEURONS, PHARMACEUTICAL COMPOSITION ON ITS BASE, AND THE METHOD OF ITS APPLICATION - The invention is related to the medicinal means of treatment of diseases, traumas, as well as consequences of traumas of the central nervous system, and can be also used as a means of stimulating neurons regeneration. There is proposed a peptide glutamyl-aspartyl-arginine with general formula H-GIu-Asp-Arg-OH sequence 1 [SEQ ID NO:1] capable of stimulating the regeneration of neurons. There is also proposed a pharmaceutical composition stimulating the regeneration of neurons containing peptide glutamyl-aspartyl-arginine with general formula H-GIu-Asp-Arg-OH sequence 1 [SEQ ID NO:1] as its active base, as well as a pharmaceutically acceptable carrier. There is proposed a method of stimulating the regeneration of neurons consisting in the administration to a patient of the pharmaceutical composition, containing peptide glutamyl-aspartyl-arginine with general formula H-Glu-Asp-Arg-OH sequence 1 [SEQ ID NO:1] as its active base, in the dose of 0.01-100 μg/kg of body weight at least once a day during a period necessary for attaining the therapeutic effect, such administration being performed parenterally. | 04-23-2009 |
20090105158 | PEPTIDE SUBSTANCE REVEALING A STRESS PROTECTIVE EFFECT, PHARMACEUTICAL COMPOSITION ON ITS BASE, AND THE METHOD OF ITS APPLICATION - The invention is related to the medicinal means of prevention and treatment for functional or stress induced disorders, which occur as a result of extreme impacts, and may be used as a medication revealing a stress protective effect. There is proposed a peptide glutamyl-aspartyl-glycine with general formula H-Glu-Asp-Gly-OH sequence 1 [SEQ ID NO:1], revealing a stress protective effect. There is proposed a pharmaceutical composition revealing a stress protective effect, characterized in that such composition contains an effective amount of peptide glutamyl-aspartyl-glycine with general formula H-Glu-Asp-Gly-OH sequence 1 [SEQ ID NO:1] as its active base, as well as a pharmaceutically acceptable carrier. In this case such pharmaceutical composition exists in the form suitable for parenteral or intranasal administration. There is proposed a method of prevention and/or treatment for functional or stress induced disorders, which occur as a result of extreme impacts, such method consisting in the administration to a patient of a pharmaceutical composition containing an effective amount of peptide glutamyl-aspartyl-glycine with general formula H-Glu-Asp-Gly-OH sequence 1 [SEQ ID NO:1] as its active base in the dose of 0.01-100 μg/kg of body weight, at least once a day during a period necessary for attaining a therapeutic effect. In this case such administration is performed parenterally or intranasally. | 04-23-2009 |
20090105159 | Neuroprotective Compounds and Uses Thereof - The present invention relates to a neuroprotective compound consisting of the amino acid sequence DLHW. | 04-23-2009 |
20090111757 | HCV PROTEASE INHIBITORS - Compounds of formula (I): | 04-30-2009 |
20090111758 | USE OF THERAPEUTICALLY USEFUL PEPTIDES - The invention relates to preventing and treating endothelial dysfunction by using biologically active peptides and products containing them. In particular, the tripeptides Ile-Pro-Pro (IPP), Val-Pro-Pro (VPP) or mixtures, concentrates or other products containing them are used. A specific aspect of the present invention is to enhance the elasticity of blood vessels by using said biologically active peptides. | 04-30-2009 |
20090124559 | Soft Protease Inhibitors and Pro-Soft Forms Thereof - The invention provides compounds and methods for inhibiting proteases. One aspect of the invention features pro-soft inhibitors which react with an activating protease to release an active inhibitor moiety in proximity to a target protease. In certain instances, compounds inhibit proteasomes and/or post-proline cleaving enzymes (PPCE), such as dipeptidyl peptidase IV. The compounds of the invention provide a better therapeutic index, owing in part to reduced toxicity and/or improved specificity for the targeted protease. | 05-14-2009 |
20090131330 | PAR-2 AGONIST - Disclosed is a compound represented by the following general formula (1): Ar—CO-AA | 05-21-2009 |
20090131331 | Novel Nutraceutical Compositions - The present invention describes the use of MAP and/or ITP or a salt thereof as a nutraceutical, preferably a medicament. | 05-21-2009 |
20090137495 | Organic Compounds and Their Uses - The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases. | 05-28-2009 |
20090143311 | Compositions comprising tripeptides inhibiting ace - The present invention describes the use of MAP and/or ITP or a salt thereof as a nutraceutical, preferably a medicament. | 06-04-2009 |
20090143312 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE - The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus. | 06-04-2009 |
20090149394 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES - The present invention provides novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of diseases that can be treated by modulation of QC-activity, e.g. diseases selected from the group consisting of duodenal cancer with or w/o | 06-11-2009 |
20090156508 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF - The invention relates to synthetic peptide amides that are ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P | 06-18-2009 |
20090156509 | Tri-peptide Inhibitors of Serine Elastases - The present invention provides compounds of formula (I): | 06-18-2009 |
20090170783 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS - The present invention provides novel tetrahydrocarbazole compounds according to formula (I) as ligands of G-protein coupled receptors (GPCR) which are useful in the treatment and/or prophylaxis of physiological and/or pathological conditions in mammals mediated by GPCR or of physiological and/or pathological conditions which can be treated by modulation of these receptors. | 07-02-2009 |
20090170784 | Crystalline and amorphous forms of peptide - The present invention relates to the crystalline and amorphous structures of SEQ ID NO:1 (FLPS), methods of making the same and use in treatment of various diseases and conditions. | 07-02-2009 |
20090170785 | PEPTIDE SUBSTANCE REVEALING AN IMMUNOGEROPROTECTIVE EFFECT, PHARMACEUTICAL COMPOSITION ON ITS BASE AND THE METHOD OF ITS APPLICATION - The invention is related to the medicinal means of prevention and correction of age-related disorders of cellular and humoral immunity and may be used as a medication revealing an immunogeroprotective effect. There is proposed a peptide glutamyl-aspartyl-proline with general formula H-Glu-Asp-Pro-OH sequence 1 [SEQ ID NO:1], revealing an immunogeroprotective effect. There is proposed a pharmaceutical composition revealing an immunogeroprotective effect containing an effective amount of peptide glutamyl-aspartyl-proline with general formula H-Glu-Asp-Pro-QH sequence 1 [SEQ ID NO:1] as its active base. In this case such pharmaceutical composition exists in the form suitable for parenteral administration. There is proposed a method of prevention and/or correction of age-related disorders of cellular and humoral immunity by stimulating the processes of lymphocytes proliferation and differentiation, such method consisting in the administration to a patient of a pharmaceutical composition containing an effective amount of peptide glutamyl-aspartyl-proline with general formula: H-Glu-Asp-Pro-OH sequence 1 [SEQ ID NO:1] in the dose of 0.01-100 μg/kg of body weight as an active base at least once a day during a period necessary for attaining a therapeutic effect. In this case the pharmaceutical composition is administered parenterally. | 07-02-2009 |
20090176714 | METHOD OF REDUCING THE EFFECTS OF ABeta AND COMPOSITIONS THEREFORE - The invention provides methods and materials related to inhibiting the effects of Aβ such as neuronal cell death and tau phosphorylation. For example, the invention provides polypeptides, compositions containing polypeptides, transgenic animals, and methods for preventing an Aβ effect (e.g., neuronal cell death in a mammal). | 07-09-2009 |
20090176715 | Pharmaceutical Compositions and Methods Utilizing a D-Amino Acid - The present invention provides a pharmaceutical composition for oral administration comprising a D-amino acid combined with an antioxidant selected from the group consisting of vitamin E, vitamin C, a glutathione or a precursor thereof. | 07-09-2009 |
20090176716 | INHIBITORS OF CANCER CELL, T-CELL AND KERATINOCYTE PROLIFERATION - The invention relates to compounds of the general formula (I) and salts and physiologically functional derivatives thereof, | 07-09-2009 |
20090186827 | Process of inhibiting cell death in injured cartilage - Processes for inhibiting apoptotic cell death and glycosaminoglycan release from injured cartilage is provided. Inhibition is accomplished using caspase inhibitors. | 07-23-2009 |
20090186829 | Nitrosation-Inducible Inhibitors Biological Macromolecules - Biomacromolecules such as proteins are inactivated by hydrophobic ANSA derivatives of the formula: | 07-23-2009 |
20090192094 | TREATMENT OF DISEASES USING ICE INHIBITORS - This invention relates to methods and compositions for treating autoinflammatory diseases. The invention also assays for evaluating the ability of an ICE inhibitor to treat autoinflammatory diseases. | 07-30-2009 |
20090203628 | Composition, Method And Kit For Treating Skin Disorders And Improving Skin Condition - The present invention provides a composition, method and kit for treating skin disorders and improving skin condition. The composition, method and kit is particularly suited for treating acne vulgaris, seborrhea, rosacea, hirsutism, psoriasis, oily skin, dry skin, discoloration, post inflammatory hyper pigmentation, sun spots, and wrinkles. | 08-13-2009 |
20090203629 | INHIBITORS OF CATHEPSIN B - The present invention is directed to a method of using compounds of Formula (I) to inhibit Cathepsin B. Specifically the compounds of the present invention are useful as therapeutic agents for the treatment of tumor invasion, metastasis, Alzheimer's Disease, arthritis, inflammatory diseases such as chronic and acute pancreatitis, inflammatory airway disease, and bone and joint disorders, including osteoporosis, osteoarthritis, rheumatoid arthritis, psoriasis, and other autoimmune disorders, liver fibrosis, including liver fibrosis associated with HCV, all types of steatosis (including non-alcoholic steatohepatitis) and alcohol-associated steatohepatitis, non-alcoholic fatty liver disease, forms of pulmonary fibrosis including idiopathic pulmonary fibrosis, pathological diagnosis of interstitial pneumonia following lung biopsy, renal fibrosis, cardiac fibrosis, retinal angiogenesis and fibrosis/gliosis in the eye, schleroderma, and systemic sclerosis. The compounds of Formula (I) are also useful for treating subjects with both HCV and fibrosis in a mammal, particularly liver fibrosis, and subjects affirmatively diagnosed or at risk for both HCV and liver fibrosis. | 08-13-2009 |
20090215703 | PAR-2 Agonist - The present invention relates to a pharmaceutical composition for preventing/treating conditions associated with PAR-2. The present invention also relates to a method for preventing/treating the condition using the pharmaceutical composition and use for manufacturing the pharmaceutical composition. The pharmaceutical composition comprises a compound represented by the following general formula (1), salt or solvate thereof and a pharmaceutically acceptable carrier: Ar—CO-AA | 08-27-2009 |
20090221513 | Treatment of Neurodegenerative Disorders - Peptides having the sequence D-Arg-L-Glu-L-Arg, or the sequence L-Arg-D-Glu-L-Arg and derivatives thereof, are disclosed. Such peptides are useful in treatment of neurodegenerative disorders, and as cognitive enhancers. Preferred peptides include a protective group. | 09-03-2009 |
20090221514 | METHODS FOR PREVENTION AND TREATMENT OF ACUTE RENAL INJURY - The disclosure relates to a method for protecting a kidney from renal injury. For example, acute renal injury may be associated with decreased or blocked blood flow in the subject's kidney or exposure to a nephrotoxic agent, such as a radiocontrast dye. The methods include administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof. | 09-03-2009 |
20090239807 | Methods and kits for diagnosing and/or assessing severity and treating gaucher disease - Methods and kits for treating Gaucher disease are provided. The methods are based on using agents capable of inhibiting proteasomal degradation of glucocerebrosidase and/or elevating a level of mis-folded yet active glucocerebrosidase in cell lysosomes. Also provided are methods and kits for diagnosing and/or assessing a severity and determining prognosis of Gaucher disease or other diseases associated with abnormally folded proteins which are retained in the ER. | 09-24-2009 |
20090239808 | CALCIUM RECEPTOR ACTIVATOR - A calcium receptor activator and compositions containing at least one of the following: γ-Glu-Cys-Gly, γ-Glu-Cys(SNO)-Gly, γ-Glu-Ala, γ-Glu-Gly, γ-Glu-Cys, γ-Glu-Met, γ-Glu-Thr, γ-Glu-Val, γ-Glu-Orn, Asp-Gly, Cys-Gly, Cys-Met, Glu-Cys, Gly-Cys, Leu-Asp, D-Cys, γ-Glu-Met(O), γ-Glu-Val-Val, γ-Glu-Val-Glu, γ-Glu-Val-Lys, γ-Glu-γ-Glu-Val, γ-Glu-Val-NH | 09-24-2009 |
20090239809 | Process For Preparing Peptide Products For Promoting Cholecystokinin Secretion And Use Of The Peptide Products - A process for producing a peptide product having cholecystokinin secretion promoting effect, said process comprising hydrolyzing soybean residues with one or more proteases so that the peptide product having cholecystokinin secretion promoting effect is obtained. Also disclosed is the composition containing the peptide product and the use thereof. | 09-24-2009 |
20090247468 | PHARMACEUTICAL COMPOSITIONS - Methods of spray drying are described. | 10-01-2009 |
20090253640 | INHIBITORS OF POLYISOPRENYLATED METHYLATED PROTEIN METHYL ESTERASE - Inhibitors of the enzyme prenylated methylated protein methyl esterase (PMPMEase), the last step in the prenylation process for many eukaryotic proteins, having the general structure R | 10-08-2009 |
20090253641 | METHODS FOR PREVENTING OR TREATING INSULIN RESISTANCE - The invention provides methods of preventing or treating insulin resistance in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p | 10-08-2009 |
20090264373 | SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF - The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P | 10-22-2009 |
20090270336 | Piperazine derivatives - This invention relates to novel compounds that are piperazine derivatives, and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel piperazine compounds that are derivatives of the chemokine CCR5 receptor antagonist, vicriviroc. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administering chemokine CCR5 receptor antagonists, such as vicriviroc. The invention also relates to the use of one or more of the disclosed compounds as reagents in analytical studies involving vicriviroc. | 10-29-2009 |
20090270337 | Composition Comprising Carbohydrates and Peptides which Comprise Tryptophan - An edible composition comprising peptides rich in tryptophan, which edible composition further comprises a rapidly available glucose composition and a slowly available glucose composition. | 10-29-2009 |
20090291902 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE - The present invention relates to compounds of formula I: | 11-26-2009 |
20090298781 | COMPOUNDS FOR THE INHIBITION OF APOPTOSIS - The present invention relates to compounds of formula (I) as well as to drug conjugates based on compounds of formula (I) acting as apoptosis inhibitors, as well as to processes for their preparation, to pharmaceutical compositions containing them and their use in medicine. | 12-03-2009 |
20090305995 | AGONISTS AND ANTAGONISTS OF THE SOMATOSTATIN RECEPTOR - The invention relates to substituted F3-Phe-trp-F 3-Lys-beta-tri-peptides and derivatives thereof, a process for their preparation, pharmaceutical preparations which contain these compounds which are agonists/antagonists of somatostatin receptors, as active agents for the treatment of disorders which can be influenced by a modulation of somatostatin receptor activity, in particular somatostatin receptor sst4 activity, by the compounds of the invention. | 12-10-2009 |
20090312270 | Peptides having an ace inhibiting effect - Use of the tripeptide MAP optionally in combination with tripeptide ITP and salts thereof for the preparation of a functional food angiotensin-converting enzyme inhibitor. Also provided is the use of the tripeptide MAP and optionally the tripeptide ITP or salts thereof as an angiotensin-converting enzyme inhibitor in functional foods. | 12-17-2009 |
20090312271 | Method For Elevating Prolactin in Mammals - Methods for elevating and stabilizing prolactin levels in a mammal including methods of treating disorders and conditions associated with reduced serum levels of prolactin are provided. Also provided are methods of using certain synthetic tetrapeptide amides which are peripherally selective kappa opioid receptor agonists to elevate or stabilize serum prolactin levels. | 12-17-2009 |
20090318367 | Use of SH2 STAT3/STAT1 Peptidomimetics as Anticancer Drugs - The subject invention concerns compositions and methods for blocking cancer cell growth or proliferation and/or inducing cancer cell death. Compositions of the present invention are peptidomimetics that inhibit STAT function. Peptidomimetics of the invention display selective inhibition of specific STAT isoform homo-dimerization. The peptidomimetic probes of STAT1 function, described herein, provide the means to preferentially inhibit STAT1 over STAT3 through the exploration of the C-terminus. | 12-24-2009 |
20090318368 | ANGIOTENSIN-CONVERTING ENZYME INHIBITORY PEPTIDES - It is intended to provide ACE inhibitory tripeptides which are not easily digested by digestive enzymes after being orally taken and thus have fewer tendencies to lose their ACE inhibitory activity in vivo. | 12-24-2009 |
20090325888 | Peptides having a health benefit and compositions comprising them - The present invention provides the tripeptide MAP and/or the tripeptide ITP and/or salts thereof for use as a health benefit agent, especially in functional food products. The tripeptides have particular application in the areas of the prevention of obesity or body weight control and cardiovascular health maintenance, especially the inhibition of angiotensin-converting enzyme and the control of blood cholesterol levels. Functional Food products comprising these tripeptides and having health benefits in these areas, and a process for making these products, are also provided. The tripeptides can be conveniently incorporated into food products to provide the aforementioned health benefits to the consumer thereof. | 12-31-2009 |
20090325889 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR - The present invention provides novel compounds which mimic peptides with a C-terminal penultimate proline, such compounds being useful as protease inhibitors, particularly as inhibitors of serine proteases, and more particularly as inhibitors of the NS3 serine protease from hepatitis C. The compounds find utility as antiviral agents directed at hepatitis C. The invention further provides methods of employing such inhibitors, alone or in combination with other therapeutic agents, to treat hepatitis C infection in a subject in need of such treatment. | 12-31-2009 |
20100022458 | METHODS FOR TREATING ACUTE ACOUSTIC TRAUMA - The current invention provides methods and compositions for treating sensorineural hearing loss including but not limited to acute acoustic trauma (AAT). The composition includes compounds which function as free radical traps such as phenyl butyl nitrone (PBN), free radical scavengers, such as edaravone, resveratrol, ebselen and iron chelator and compounds from the family of antioxidant compounds including, but not limited to, N-acetylcysteine (NAC), Acetyl-L-Carnitine (ALCAR), glutathione monoethylester, ebselen, D-methionine and carbamathione. The compositions of the current invention may be delivered by injections or orally. | 01-28-2010 |
20100035825 | Treatment Of Disease By Inducing Cell Apoptosis - The present invention relates generally to the treatment and prevention of diseases characterized by excess cell proliferation and/or activation. In particular, the present invention provides compositions and methods to suppress the activation and/or proliferation of various cells. In some preferred embodiments, the present invention provides compositions and methods to suppress the activation and/or proliferation of mesenchymally derived cells (including, but not limited to hepatic stellate cells), as well as cells with abnormal growth characteristics. In some particularly preferred embodiments, the present invention provides compositions and methods to inhibit or eliminate fibrosis. In alternative preferred embodiments, the present invention provides compositions and methods to induce fibrosis. In still further embodiments, the present invention provides methods and compositions to treat and/or prevent cancer. | 02-11-2010 |
20100041615 | PROTEIN-BINDING METHOTREXATE DERIVATIVES, AND MEDICAMENTS CONTAINING THE SAME - The invention relates to methotrexate derivatives which contain a protein-binding group and can be enzymatically cleaved in the body such that the active substance or a low-molecular active substance derivative is released. Also disclosed is a method for producing methotrexate derivatives, the use thereof, and medicaments comprising methotrexate derivative. | 02-18-2010 |
20100069309 | Method for medical treatment utilizing glutathione - A method of treating a condition or conditions caused by damage to cells by a process of oxidative stress and glutathione depletion. In some exemplary embodiments, the condition or conditions may be treated by administering reduced L-glutathione to a patient through injection or intravenous infusion. In other exemplary embodiments, the condition or conditions may be treated by administering reduced glutathione monoethyl ester through injection or intravenous infusion. | 03-18-2010 |
20100075910 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF - The invention relates to synthetic peptide amides that are ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P | 03-25-2010 |
20100087382 | Inhibitors of Hepatitis C NS3 Protease - Compounds of formula I: | 04-08-2010 |
20100093643 | CARDIOPROTECTIVE COMPOUNDS - Tissue protective compounds comprise the tetrapeptide structure A-B-C-D wherein each hydrogen of the N-terminus NH2 of amino acid residue A may independently optionally be replaced by C1-S alkyl or C1-S acyl, A—is an aromatic amino acid residue wherein the aromatic ring may optionally be substituted with one or more nitro group, B—is a diamino acid residue wherein the side chain amino group is substituted with C1-S acyl, C1-S alkyl, 'B′-Ci-s acyl or —B′-Ci-s alkyl, wherein B′ is an an amino acid residue which may optionally be substituted with one or more nitro group, C—is Gly wherein the peptide N—H may optionally be changed to N-methyl, D—is Phe which is substituted on the aromatic ring with at least one nitro group and optionally further substituted on the aromatic ring with one or more group independently selected from nitro, fluoro, chloro, bromo, iodo, CF3 or CN, wherein the peptide N—H may optionally be changed to N-methyl, and the C-terminus C═O of amino acid residue D is substituted with NH2, NHC1-5 alkyl, NH—NH2, NH—NHC1-5 alkyl, or 0-C1-S alkyl, or the C-terminus is COOH or CH2OH, or a pharmaceutically acceptable salt thereof. | 04-15-2010 |
20100093644 | TEMPLATE-FIXED PEPTIDOMIMETICS - Template-fixed β-hairpin peptidomimetics of the general formula (I) wherein Z is a template-fixed chain of 4 α-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to agonize or to antagonize GPCR receptors such as CXCR3, urotensin and CCR10. They can be used as medicaments to treat or prevent diseases such as cardiovascular disorders, dermatological disorders, endocrine system and hormone disorders, metabolic diseases, inflammatory diseases, neurological diseases, respiratory diseases, haematological diseases and cancer. These β-hairpin peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy. | 04-15-2010 |
20100113370 | METHODS AND COMPOUNDS FOR MODULATING INFLAMMATORY PROCESSES - Provided is a method of treating a patient having an inflammatory disease by using a compound which inhibits the ABCC4-mediated release of leukotrienes, a medicament containing such compound and methods for screening such compounds. | 05-06-2010 |
20100120698 | LOW-FAT FOOD - A low-fat food containing an amino acid or a peptide which is able to activate a calcium receptor, examples of which include γ-Glu-X-Gly, γ-Glu-Val-Y, γ-Glu-Ala, γ-Glu-Gly, γ-Glu-Cys, γ-Glu-Met, γ-Glu-Thr, γ-Glu-Val, γ-Glu-Orn, Asp-Gly, Cys-Gly, Cys-Met, Glu-Cys, Gly-Cys, Leu-Asp, D-Cys, γ-Glu-Met(O), γ-Glu-γ-Glu-Val, γ-Glu-Val-NH | 05-13-2010 |
20100120699 | METHOD FOR SYNTHESIZING KPV TRIPEPTIDE DIAMIDE DERIVATES - The object of the invention is to provide an improved method for synthesizing a KPV tripeptide diamide derivate having the formula (I) such as defined in the specification. The synthesis method according can be implemented with any of the stereoisomers of each of the Lysine (K), Proline (P) or Valine (V) amino acid residues. | 05-13-2010 |
20100137226 | FATIGUE-REDUCING AGENT - A pharmaceutical product, a functional food or the like has been demanded which can reduce the fatigue in a tired person and enables the tired person to lead a fulfilled life. Disclosed is a fatigue-reducing agent. The fatigue-reducing agent comprises ornithine or a salt thereof and glutathione or a salt thereof as active ingredients. | 06-03-2010 |
20100137227 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS - The invention relates to compositions comprising of SEQ NO: 1-244, 248-249, and any homologs, analogs, and fragments thereof. Such compositions can be used to treat, prevent, and modulate pain, inflammation, and metabolic processes in various organisms including plants and animals. Such compositions can be formulated with an acceptable pharmaceutical excipient for administration to a human or a plant. The compositions can be administered topically or for systemic use. | 06-03-2010 |
20100144647 | Dual Acting Prodrugs - The present invention relates to a prodrug which comprises at least two different pharmaceutically and/or diagnostically active compounds independently bound by cleavable linkers and a protein-binding moiety which is capable of binding to carrier a molecule. | 06-10-2010 |
20100144648 | COMPOUNDS FOR ENZYME INHIBITION - One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention. | 06-10-2010 |
20100144649 | COMPOUNDS FOR ENZYME INHIBITION - One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention. | 06-10-2010 |
20100168038 | USE OF COMPOUNDS IN COMBINATION WITH GAMMA-IRRADIATION FOR THE TREATMENT OF CANCER - TPP II (tripeptidyl peptidase inhibitors are useful in enhancing the efficacy of gamma-irradiation cancer therapy or increasing the in vivo gamma-irradiation susceptibility of tumour cells. Suitable compounds comprise tripeptide compounds of general formula R | 07-01-2010 |
20100184706 | FAP-ACTIVATED CHEMOTHERAPEUTIC COMPOUNDS, AND METHODS OF USE THEREOF - One aspect of the present invention relates to compounds for delivering chemotherapeutic agents to cancerous cells to reduce discomfort and deleterious side effects associated with systemic administration of such agents. Another aspect of the invention relates to methods of treating a subject with cancer by administering a therapeutically effective amount of a chemotherapeutic agent that predominately targets cancerous cells over healthy cells. Additionally, one aspect of the present invention relates to methods of inhibiting the life-cycle of a cancerous cell, as well preparing a chemotherapeutic prodrug. | 07-22-2010 |
20100184707 | ANTICONVULSIVE PHARMACEUTICAL COMPOSITIONS - The use of a substance selected from the group consisting of taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis, for manufacturing a pharmaceutical composition for preventing or inhibiting the undesirable side-effects caused to a human or an animal organism by an active ingredient that induces a high level of extracellular GABA or increases GABA receptor activation. | 07-22-2010 |
20100184708 | USE OF GLY-PRO-GLU-OH (GPE) AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Gly-Pro-Glu-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Gly-Pro-Glu-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 07-22-2010 |
20100190723 | PREVENTIVE OR THERAPEUTIC COMPOSITION FOR LIVER DISEASE - This invention provides a composition having preventive and/or therapeutic effects on liver disease, which is highly effective, free of side effects, easily ingestible, and capable of long-term ingestion from the viewpoint of a cost and safety. This invention relates to a peptide having the amino acid sequence represented by the following formula: pyroGlu-(X)n-A, wherein X is the same or different and represents Gln or Asn; A represents Gln, Asn, Leu, Ile, or Val; and n is an integer from 0 to 2 or a salt thereof. | 07-29-2010 |
20100190724 | USE OF MELANOCYTE-STIMULATING HORMONE RELEASE-INHIBITING FACTOR AS A THERAPEUTIC AGENT IN THE TREATMENT OF PSEUDOMONAS AERUGINOSA INFECTION - The present invention is directed to the use of the peptide compound Pro-Leu-Gly-NH | 07-29-2010 |
20100197608 | USE OF MELANOTROPHIN-POTENTIATING FACTOR AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Lys-Lys-GIy-Glu-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Lys-Lys-Gly-Glu-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 08-05-2010 |
20100204159 | ORGANIC COMPOUNDS AND THEIR USES - The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases. | 08-12-2010 |
20100210567 | USE OF A TUFTSIN AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Thr-Lys-Pro-Arg-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Thr-Lys-Pro-Arg-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 08-19-2010 |
20100210568 | THYROTROPIN RELEASING HORMONE FOR THERAPEUTIC APPLICATIONS - The present invention is directed to the use of the peptide compound Pyr-His-Pro-NH | 08-19-2010 |
20100216725 | 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION - The invention provides 4-amino-4-oxobutanoyl peptides of Formula I | 08-26-2010 |
20100222282 | METHOD OF DIAGNOSIS AND METHOD OF TREATMENT - The present invention relates to a method for diagnosing higher susceptibility for diseases and conditions associated with low levels of AKG in a human or animal comprising the following steps: a) obtaining a biological sample from said human or animal; b) measuring the alpha-ketoglutaric acid (AKG) level in the biological sample; and c) comparing said measured AKG level with normal average AKG levels, wherein a level of AKG in said sample lower than an average level is indicative of a higher susceptibility for various diseases. Further the invention relates to a use of a substance comprising at least one member selected from the group consisting of AKG and derivates, metabolites, analogues or salts thereof for the manufacture of a pharmaceutical preparation or a food or feed supplement for the treatment or prophylaxis of diseases and conditions associated with low levels of AKG in a human or animal with low levels of AKG compared with normal average AKG levels. | 09-02-2010 |
20100234307 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY - This invention relates to certain biphenyl amino acid compounds, compositions, and methods for treating or preventing obesity and related diseases. | 09-16-2010 |